September 25, 2015Open Access

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Motzer et al. (Fri,) studied this question.

www.synapsesocial.com/papers/69d94c0e00ab073a27835e4f — DOI: https://doi.org/10.1056/nejmoa1510665

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial· 2014 · 1,074 citations
Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).· 2015 · 147 citations
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma· 2004 · 802 citations
Molecular mechanisms of T‐cell tolerance

Authors

Robert J. Motzer

Bernard Escudier

Ray McDermott

Journals

New England Journal of Medicine

Actions

Institutions

Harvard University

University of Washington

Johns Hopkins University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion